Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Goldman Sachs analyst Andrea Newkirk has reinstated a Buy rating on Revolution Medicines (NASDAQ: RVMD) and set a price target of $267 for the stock. This strategic move indicates a positive outlook for the company's future performance.